Calmark receives order from Greece for Neo-Bilirubin

Calmark Sweden AB (publ) announces today that an order has been received from the Company's distributor in Greece, Prime Biosciences, for the Neo products. Today’s order is of less economic importance, but significant in a launch perspective.

As previously disclosed, Calmark has entered into an exclusive distributor agreement with Prime Biosciences. The cooperation between the companies has been going on for some time, and the launch plan has been thoroughly prepared. Today's order shows that end customers have an interest in Calmark's products and that sales operations in Greece are under way. 

“Prime Biosciences is a strongly committed distributor, which has already held a large number of meetings and discussions relating to our products with hospital clients. The first order will be delivered to interested end customers shortly,” says Magdalena Tharaldsen, Director International Business Development. “I am delighted that work is proceeding swiftly!”

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 31-05-2022 16:02 CET.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.